The Food and Drug Administration (FDA) of the United States has granted approval and authorization for the use of a new emergency COVID-19 vaccine. This vaccine aims to encompass protection against the new variants of the virus, including the newly identified Omicron XBB.1.5 variant, as well as the subvariants BA.2.86 and EG.5.1. It is formulated for the 2023-2024 vaccine year and requires a single dose for individuals aged 5 years and above.
Albert Bourla, the CEO of Pfizer, stated that the delivery of this new vaccine is expected in the coming days.
TLDR: The FDA has approved a new emergency COVID-19 vaccine to combat the increasing number of hospitalizations in the United States. The vaccine, developed by Moderna and Pfizer, can protect against multiple variants, including Omicron XBB.1.5, and is expected to be available within days.